Expertise in
1
conditions

Reinhard Ruckser

Vienna, AT 
Expertise in
1
conditions
Vienna, AT 

Overview

Reinhard Ruckser practices practicing medicine in Vienna, Austria.

Mr. Ruckser is highly rated in 1 condition, according to our data. His clinical expertise encompasses Essential Thrombocythemia, Multiple Myeloma, Blood Clots, and Glioblastoma.

He is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Vienna, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized Phase II, 2-armed Study in Transplant Ineligible (TI) Patients With Newly Diagnosed Multiple Myeloma (NDMM) Comparing Carfilzomib + Thalidomide + Dexamethasone (KTd) Versus Carfilzomib + Lenalidomide + Dexamethasone (KRd) Induction Therapy With Respect to Response Rates and Investigating a Carfilzomib (K) Monotherapy Maintenance Strategy
A Randomized Phase II, 2-armed Study in Transplant Ineligible (TI) Patients With Newly Diagnosed Multiple Myeloma (NDMM) Comparing Carfilzomib + Thalidomide + Dexamethasone (KTd) Versus Carfilzomib + Lenalidomide + Dexamethasone (KRd) Induction Therapy With Respect to Response Rates and Investigating a Carfilzomib (K) Monotherapy Maintenance Strategy
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Drug
Study Drugs: Carfilzomib, Thalidomide, Lenalidomide, Dexamethasone
Study Phase: Phase 2

11 Total Publications

QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study.
QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study.
Journal: EJHaem
Published: February 12, 2024

Frequently Asked Questions about Reinhard Ruckser

Is Reinhard Ruckser a top-rated expert for Essential Thrombocythemia?

MediFind is an objective health platform that identifies experts based on real-world data. Reinhard Ruckser is classified as an Advanced expert for Essential Thrombocythemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Reinhard Ruckser participate in research or clinical trials?

Yes. Reinhard Ruckser has published 11 articles and abstracts on conditions like Essential Thrombocythemia. You can view a list of Reinhard Ruckser's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ruckser's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile